UCB (OTCMKTS:UCBJF) Shares Gap Down – Here’s What Happened

UCB SA (OTCMKTS:UCBJF)’s stock price gapped down before the market opened on Tuesday . The stock had previously closed at $313.72, but opened at $294.11. UCB shares last traded at $310.09, with a volume of 8 shares traded.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on UCBJF shares. Wolfe Research started coverage on shares of UCB in a research note on Monday, February 23rd. They set an “outperform” rating on the stock. The Goldman Sachs Group reaffirmed a “buy” rating on shares of UCB in a research note on Monday, February 16th. Six analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has a consensus rating of “Buy”.

UCB Stock Up 6.1%

The firm’s 50-day moving average price is $294.74 and its 200-day moving average price is $297.92. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.